Morgan Stanley Pds Biotechnology Corp Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Morgan Stanley holds 17,315 shares of PDSB stock, worth $25,972. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,315

Previous 17,894 3.24%

Holding current value

$25,972

Previous $29,000 31.03%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.18 - $1.8 $683 - $1,042	-579 Reduced 3.24%	17,315 $20,000
Q4 2024 Feb 14, 2025	SELL	$1.63 - $4.11 $15,546 - $39,201	-9,538 Reduced 34.77%	17,894 $29,000
Q3 2024 May 14, 2025	SELL	$2.93 - $4.23 $136,409 - $196,931	-46,556 Reduced 62.92%	27,432 $104,000
Q3 2024 Nov 14, 2024	SELL	$2.93 - $4.23 $136,409 - $196,931	-46,556 Reduced 62.92%	27,432 $104,000
Q2 2024 May 14, 2025	BUY	$2.55 - $4.02 $143,039 - $225,497	56,094 Added 313.48%	73,988 $216,000
Q2 2024 Oct 17, 2024	BUY	$2.55 - $4.02 $3,103 - $4,892	1,217 Added 1.67%	73,988 $216,000
Q2 2024 Aug 14, 2024	BUY	$2.55 - $4.02 $3,103 - $4,892	1,217 Added 1.67%	73,988 $216,000
Q1 2024 Oct 17, 2024	SELL	$3.85 - $6.59 $4,685 - $8,020	-1,217 Reduced 1.64%	72,771 $288,000
Q1 2024 Aug 16, 2024	SELL	$3.85 - $6.59 $47,643 - $81,551	-12,375 Reduced 14.53%	72,771 $288,000
Q1 2024 May 15, 2024	SELL	$3.85 - $6.59 $47,643 - $81,551	-12,375 Reduced 14.53%	72,771 $288,000
Q4 2023 Aug 16, 2024	BUY	$3.95 - $6.58 $44,074 - $73,419	11,158 Added 15.08%	85,146 $423,000
Q4 2023 Feb 13, 2024	BUY	$3.95 - $6.58 $64,495 - $107,438	16,328 Added 23.73%	85,146 $423,000
Q3 2023 Nov 15, 2023	BUY	$4.8 - $6.4 $7,425 - $9,900	1,547 Added 2.3%	68,818 $347,000
Q2 2023 Aug 14, 2023	SELL	$5.03 - $9.9 $184,042 - $362,231	-36,589 Reduced 35.23%	67,271 $338,000
Q1 2023 May 15, 2023	SELL	$5.68 - $11.99 $680,890 - $1.44 Million	-119,875 Reduced 53.58%	103,860 $638,000
Q4 2022 Feb 14, 2023	BUY	$3.28 - $13.2 $683,273 - $2.75 Million	208,315 Added 1350.94%	223,735 $2.95 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $3,115 - $6,073	1,049 Added 7.3%	15,420 $46,000
Q2 2022 Oct 27, 2022	SELL	$3.05 - $6.68 $6,874 - $15,056	-2,254 Reduced 13.56%	14,371 $52,000
Q2 2022 Aug 15, 2022	SELL	$3.05 - $6.68 $6,874 - $15,056	-2,254 Reduced 13.56%	14,371 $52,000
Q1 2022 Oct 27, 2022	BUY	$4.78 - $8.43 $10,774 - $19,001	2,254 Added 15.68%	16,625 $103,000
Q1 2022 May 13, 2022	SELL	$4.78 - $8.43 $18,283 - $32,244	-3,825 Reduced 18.7%	16,625 $103,000
Q4 2021 Feb 14, 2022	BUY	$7.76 - $14.35 $114,258 - $211,289	14,724 Added 257.14%	20,450 $166,000
Q3 2021 Nov 15, 2021	BUY	$9.33 - $17.08 $53,423 - $97,800	5,726 New	5,726 $85,000

Others Institutions Holding PDSB

# of Institutions

Shares Held

8.24M

Call Options Held

151K

Put Options Held

1.2K

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $42.7M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account